🚀 VC round data is live in beta, check it out!
Atrium Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Atrium Therapeutics and similar public comparables like Recordati, Financiere de Tubize, Lupin, BioMarin Pharmaceutical and more.
Atrium Therapeutics Overview
About Atrium Therapeutics
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Founded
2025
HQ
Employees
N/A
Website
N/A
Sectors
Financials (FY)
EV
$9B
Atrium Therapeutics Financials
Atrium Therapeutics reported last fiscal year revenue of $19M and negative EBITDA of ($76M).
In the same fiscal year, Atrium Therapeutics generated ($76M) in EBITDA losses and had net loss of ($77M).
Atrium Therapeutics P&L
In the most recent fiscal year, Atrium Therapeutics reported revenue of $19M and EBITDA of ($76M).
Atrium Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $19M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($76M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (411%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (413%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($77M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (412%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Atrium Therapeutics Stock Performance
Atrium Therapeutics has current market cap of $11B, and enterprise value of $9B.
Atrium Therapeutics' stock price is $72.86.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9B | $11B | 0.0% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAtrium Therapeutics Valuation Multiples
Atrium Therapeutics trades at 506.5x EV/Revenue multiple, and (123.3x) EV/EBITDA.
Atrium Therapeutics Financial Valuation Multiples
As of March 8, 2026, Atrium Therapeutics has market cap of $11B and EV of $9B.
Equity research analysts estimate Atrium Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Atrium Therapeutics has a P/E ratio of (146.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11B | XXX | $11B | XXX | XXX | XXX |
| EV (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 506.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (123.3x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (122.8x) | XXX | XXX | XXX |
| P/E | — | XXX | (146.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (221.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Atrium Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Atrium Therapeutics Margins & Growth Rates
Atrium Therapeutics' revenue in the last fiscal year grew by 71%.
Atrium Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 71% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (411%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 50% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 224% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 289% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 513% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Atrium Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Recordati | XXX | XXX | XXX | XXX | XXX | XXX |
| Financiere de Tubize | XXX | XXX | XXX | XXX | XXX | XXX |
| Lupin | XXX | XXX | XXX | XXX | XXX | XXX |
| BioMarin Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Orion | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Atrium Therapeutics M&A Activity
Atrium Therapeutics acquired XXX companies to date.
Last acquisition by Atrium Therapeutics was on XXXXXXXX, XXXXX. Atrium Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Atrium Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAtrium Therapeutics Investment Activity
Atrium Therapeutics invested in XXX companies to date.
Atrium Therapeutics made its latest investment on XXXXXXXX, XXXXX. Atrium Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Atrium Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Atrium Therapeutics
| When was Atrium Therapeutics founded? | Atrium Therapeutics was founded in 2025. |
| Where is Atrium Therapeutics headquartered? | Atrium Therapeutics is headquartered in United States. |
| Is Atrium Therapeutics publicly listed? | Yes, Atrium Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Atrium Therapeutics? | Atrium Therapeutics trades under RNA ticker. |
| When did Atrium Therapeutics go public? | Atrium Therapeutics went public in 2026. |
| Who are competitors of Atrium Therapeutics? | Atrium Therapeutics main competitors are Recordati, Financiere de Tubize, Lupin, BioMarin Pharmaceutical. |
| What is the current market cap of Atrium Therapeutics? | Atrium Therapeutics' current market cap is $11B. |
| What is the current revenue of Atrium Therapeutics? | Atrium Therapeutics' last fiscal year revenue is $19M. |
| What is the current EV/Revenue multiple of Atrium Therapeutics? | Current revenue multiple of Atrium Therapeutics is 506.5x. |
| Is Atrium Therapeutics profitable? | No, Atrium Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.